Sanofi Pasteur’s ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur is proud to help protect Japanese children against bacterial meningitis and improve public health in the country. Being the first to enter the Japanese pediatric vaccine market is an achievement that underlines Sanofi Pasteur’s strength and commitment to provide the highest quality innovative vaccines.”